Monsanto & Bayer Corporate Liability

The Monsanto Papers: A Chronicle of Corporate Deception

The "Monsanto Papers" is the term given to thousands of internal corporate documents obtained through litigation discovery that reveal how Monsanto systematically concealed the cancer risks of its flagship product. These documents — corporate emails, memos, strategy presentations, and internal scientific assessments — have been central to every Roundup trial and are the foundation of the fraud and punitive damage claims that have produced the largest verdicts.

As early as 1999, Monsanto commissioned an independent review of glyphosate's genotoxicity by British geneticist Dr. James Parry. When Parry concluded that glyphosate was "clastogenic" (capable of breaking chromosomes) and recommended further testing, Monsanto buried his report. Internal emails show that toxicologist Dr. William Heydens wrote to colleagues that Parry's conclusions were "not what we wanted" and that the company needed to find "a different person or approach" to produce more favorable results.

Ghostwriting and Manufactured Science

Perhaps the most damaging revelations involve Monsanto's practice of ghostwriting published scientific papers to create the appearance of independent support for glyphosate safety. In a 2015 email, Dr. William Heydens proposed that Monsanto scientists could write sections of a safety review and then recruit outside academics to "edit and sign their names" — a scheme that would produce a published paper bearing the names of seemingly independent scientists but actually authored by the company whose product was being evaluated.

Multiple published papers purporting to find glyphosate safe were later identified as partially or wholly ghostwritten by Monsanto employees. These papers were then cited by regulatory agencies including the EPA as evidence supporting the safety of glyphosate — creating a circular system where Monsanto's own conclusions, disguised as independent science, were used to justify continued sales of its product.

Cultivating Regulatory Allies

Internal documents reveal a troublingly close relationship between Monsanto and key EPA officials. Jess Rowland, who chaired the EPA's Cancer Assessment Review Committee (CARC), was in regular contact with Monsanto representatives. In a 2015 email, Monsanto regulatory affairs manager Dan Jenkins wrote that Rowland had promised to "try to kill" a separate Department of Health and Human Services review of glyphosate, reportedly telling Jenkins: "If I can kill this, I should get a medal."

The EPA's Office of Pesticide Programs issued a draft risk assessment in 2016 finding glyphosate "not likely to be carcinogenic to humans" — a conclusion that contradicted IARC and relied heavily on unpublished industry-sponsored studies. The CARC meeting that approved this finding was chaired by Rowland, who retired from the EPA shortly afterward.

Bayer's $63 Billion Acquisition and Its Consequences

In June 2018, German pharmaceutical and chemical company Bayer AG completed its acquisition of Monsanto for $63 billion. The acquisition was controversial from the outset — Bayer shareholders questioned the wisdom of acquiring a company facing thousands of cancer lawsuits, and the deal closed just two months before the first Roundup trial resulted in a $289 million verdict against Monsanto.

Within two years of the acquisition, Bayer announced a $10.9 billion settlement framework to resolve approximately 100,000 pending claims. The company's stock price, which was over 90 euros at the time of the acquisition, fell below 50 euros as the scale of Roundup liability became clear. By February 2026, Bayer proposed an additional $7.25 billion settlement, bringing total Roundup-related costs above $18 billion — nearly a third of the original acquisition price.

Bayer assumed full legal liability for all Monsanto actions, including the decades of scientific suppression and regulatory manipulation documented in the Monsanto Papers. The company continues to sell Roundup (reformulated for residential use in 2023) while simultaneously paying billions to resolve cancer claims — a contradiction that jurors have consistently found outrageous enough to warrant punitive damages.

Why Punitive Damages Have Been So Large

In all three bellwether Roundup trials, juries awarded punitive damages that dwarfed compensatory damages. Punitive damages are reserved for conduct that is "despicable" or reflects "a conscious disregard of the rights or safety of others." The evidence of Monsanto's deliberate concealment of cancer risks, ghostwriting of safety studies, and attacks on independent scientists meets this standard comprehensively.

The Johnson jury awarded $250 million in punitive damages (reduced to $39 million on appeal). The Hardeman jury awarded $75 million in punitives. The Pilliod jury awarded $2 billion in punitives (reduced to $69 million). Each jury heard the same internal documents and reached the same conclusion: Monsanto's conduct was malicious and deserving of punishment.